Tesamorelin

Key Takeaways

• Tesamorelin is a synthetic GHRH analogue with FDA approval in the US for HIV-associated lipodystrophy; it holds no MHRA marketing authorisation in the UK and is supplied as research-grade material only
• The 2026 meta-analysis of randomised controlled trials reported statistically significant visceral adipose tissue reduction with 2 mg daily subcutaneous dosing and no serious adverse events in HIV-positive adults
• Clinical evidence is limited to HIV-lipodystrophy populations; extrapolation to metabolic syndrome, healthy adults, or older non-HIV cohorts lacks controlled-trial support
• Tesamorelin preserves pulsatile GH secretion through GHRH receptor engagement, which separates it mechanistically from direct recombinant GH or GLP-1 receptor agonists
• Adverse events documented in trials include injection-site reactions, fluid retention, joint and muscle pain, and glucose elevation; long-term safety beyond 52 weeks is not characterised

---

Tesamorelin is a synthetic, DPP-4-resistant analogue of growth hormone-releasing hormone (GHRH) that stimulates pulsatile endogenous GH release. Its N-terminal hexenoyl modification blocks the dipeptidyl peptidase-4 cleavage site responsible for rapid inactivation of native GHRH [1]. It is FDA-approved in the United States for HIV-associated lipodystrophy and marketed there as Egrifta SV [1]. In the UK, tesamorelin holds no MHRA (Medicines and Healthcare products Regulatory Agency) marketing authorisation and is supplied solely as a research-use peptide [1].

This guide consolidates what UK-based researchers typically have to assemble from scattered US monographs. You will find the peptide's mechanism, the trial evidence base (including a 2026 meta-analysis of HIV-lipodystrophy randomised controlled trials reporting no serious adverse events [4]), studied dosage protocols, the side-effect profile, and the regulatory position as it stands in 2026. Explicit caveats appear wherever the evidence does not extend to the population you may have in mind.

What Is Tesamorelin? Structural Overview

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH) bearing a trans-3-hexenoic acid moiety on the N-terminal tyrosine. It is marketed in the United States under the trade name Egrifta SV and administered by subcutaneous injection [1]. The hexenoyl modification confers resistance to dipeptidyl peptidase-4 (DPP-4) cleavage, extending plasma stability relative to native GHRH(1-44) whilst preserving binding to the pituitary GHRH receptor [1].

The peptide mirrors the 44-residue endogenous hypothalamic GHRH sequence. The Mayo Clinic (31 January 2026) describes this as "a hormone similar to the one normally released from the hypothalamus gland". Because tesamorelin retains the native binding domain, it stimulates pulsatile rather than tonic GH release — a pharmacodynamic feature that separates it from direct recombinant GH administration [1].

Structural distinctions from native GHRH

Native GHRH(1-44) undergoes rapid inactivation in plasma by DPP-4 cleavage at the Tyr¹-Ala² bond. The half-life is measured in minutes, which is why native GHRH cannot be administered as a once-daily injection [1]. Tesamorelin's N-terminal hexenoyl group sterically blocks that cleavage site. This is the principal chemical rationale for its clinical viability as a once-daily subcutaneous injection [1]. Beyond the N-terminal modification, the 44-residue backbone remains unchanged from the endogenous sequence [1].

Position within the GHRH peptide class

Among research peptides acting on the GH axis, tesamorelin sits alongside other GHRH analogues such as CJC-1295 and sermorelin, which differ in length and half-life-extending modifications. Exact comparative sequence data for those analogues is not summarised in the sources reviewed here [unverified].

Researchers comparing mechanisms with GLP-1 receptor agonists such as semaglutide should note that the two classes act on entirely separate receptor systems. GLP-1 agonists engage incretin signalling; GHRH analogues engage pituitary somatotroph cells [1].

Mechanism of Action: How Tesamorelin Works

Tesamorelin binds the GHRH receptor on somatotroph cells of the anterior pituitary. This triggers endogenous growth hormone (GH) release, which in turn drives hepatic IGF-1 (insulin-like growth factor 1) production and lipolysis in visceral adipose tissue [1]. The NIH LiverTox monograph (2018) classifies tesamorelin as a synthetic GHRH analogue whose clinical effect is mediated via the GH/IGF-1 axis rather than through direct adipocyte action.

Receptor engagement at the pituitary activates the Gs-coupled cAMP (cyclic adenosine monophosphate)/PKA (protein kinase A) cascade — the canonical GHRH receptor pathway and the upstream trigger for GH secretory vesicle exocytosis [1]. Because tesamorelin's hexenoyl modification resists DPP-4 cleavage but does not alter the binding domain, downstream signalling proceeds through the same receptor-effector chain as native GHRH(1-44) [1].

Pulsatile rather than tonic GH release

Tesamorelin amplifies the body's existing pulsatile GH rhythm rather than imposing a sustained supraphysiological plateau. Negative feedback from somatostatin and IGF-1 remains intact, so peaks and troughs persist [1]. This is the mechanistic basis for the claim, repeated across the UK research-peptide literature, that GHRH analogues are "physiology-preserving" relative to exogenous recombinant GH.

Visceral adipose tissue as the downstream target

Elevated GH pulses stimulate hormone-sensitive lipase activity and reduce lipoprotein lipase in visceral depots. This produces the visceral adipose tissue (VAT) reduction documented in the HIV-lipodystrophy RCT pool summarised by the 2026 meta-analysis [4]. Subcutaneous fat is comparatively spared, which is why tesamorelin's clinical signature is VAT-selective rather than generalised weight loss [4].

Distinction from GLP-1 receptor agonists

The mechanism shares no receptor or signalling overlap with GLP-1 receptor agonists such as semaglutide or dual GIP/GLP-1 agonists. Those act on incretin pathways to modulate appetite, insulin secretion, and gastric emptying via a different G-protein-coupled receptor family [1].

Researchers comparing GH-axis peptides should also see the CJC-1295 profile, since both compounds engage the same pituitary receptor but differ in half-life-extending modifications [1].

Clinical Evidence: HIV-Lipodystrophy Indication

Tesamorelin's approved evidence base derives from two Phase III randomised controlled trials in HIV-positive adults on antiretroviral therapy with excess abdominal fat. These trials collectively underpinned the US FDA approval of Egrifta (subsequently reformulated as Egrifta SV) for HIV-associated lipodystrophy, demonstrating statistically significant VAT reduction with acceptable safety [1].

MedlinePlus, updated 15 July 2025, confirms the indication remains narrowly defined as "to decrease the amount of extra fat in the stomach area in adults with HIV" — not a general metabolic or anti-obesity licence.

Primary outcome: visceral adipose tissue reduction

The trials measured visceral adipose tissue (VAT) by abdominal CT scan at the L4-L5 level. This anatomical plane provides the most consistent cross-sectional area for serial measurement and is the radiological standard for separating visceral from subcutaneous depots [1].

A 2026 meta-analysis of randomised controlled trials in HIV-associated lipodystrophy pooled the available trial data. It reported a statistically significant VAT reduction with tesamorelin 2 mg daily subcutaneous dosing versus placebo, with improvements in trunk fat and triglycerides and no serious adverse events across the pooled population [4]. Limb fat was comparatively preserved, consistent with the VAT-selective mechanism described above.

Lipid and metabolic markers

Across the pooled RCT evidence, triglyceride reductions and modest improvements in the total cholesterol to HDL ratio were the most consistently reported secondary metabolic outcomes, reflecting the downstream effect of GH-stimulated lipolysis in visceral depots [4].

Effects on fasting glucose and HbA1c were less consistent. The meta-analysis did not identify a clinically meaningful glycaemic signal in either direction [4]. Hepatic fat outcomes were also reported, though the trials were not powered as NAFLD/MASLD studies.

Reversibility on discontinuation

VAT reductions reversed after tesamorelin was withdrawn, indicating that the effect depends on continued GHRH stimulation rather than any durable structural change in adipose biology [4]. This has obvious implications for researchers designing washout phases or extension protocols.

Population caveat and source currency

Every figure above derives from HIV-positive adults on stable antiretroviral therapy. Extrapolation to healthy volunteers, older adults, or non-HIV metabolic syndrome cohorts is not supported by the cited evidence base.

The NIH/NCBI LiverTox monograph on tesamorelin (last substantive update 2018) predates the 2026 meta-analysis and should not be relied upon for current outcome data. PubMed remains the appropriate route for post-2023 trial updates [4].

Readers comparing GHRH-axis options against incretin-based research compounds should also see the CJC-1295 and semaglutide profiles.

Emerging Research Areas (Non-HIV, 2023-2026)

Beyond the licensed HIV-lipodystrophy indication, tesamorelin research outside HIV cohorts remains preliminary. No peer-reviewed RCT in metabolic syndrome, healthy older adults, or cognitive endpoints published between 2023 and 2026 was located. Treat the areas below as hypothesis-generating only.

Metabolic syndrome and non-HIV visceral obesity

UK-facing 2026 reference pages describe interest in tesamorelin for visceral adiposity outside HIV, citing its pulsatile GH release mechanism and the consistent VAT signal seen in HIV trials [1]. No non-HIV RCT has been verified in the current evidence set. Applying the 2 mg/day subcutaneous dose used in HIV-lipodystrophy trials [4] to metabolic-syndrome cohorts is unverified extrapolation, not an evidence-based protocol.

Combination with ipamorelin (GHRP)

Combining a GHRH analogue with a GHRP such as ipamorelin is discussed in UK comparative reviews as a theoretical route to amplified GH pulses, exploiting the complementary GHRH and ghrelin-receptor pathways. No published human trial of a tesamorelin/ipamorelin protocol was identified in the 2023-2026 search set. Clinical wellness sources referencing this combination for waist circumference or lean mass are not peer-reviewed evidence and should not be cited as such.

Cognitive and neuroprotective signals

Preliminary interest in GHRH-axis effects on cognition is mentioned in 2026 UK reference material [1]. No controlled cognitive endpoint trial in non-HIV adults is present in the sources reviewed here. Any neuroprotective claim for tesamorelin specifically remains unverified against a primary trial in this evidence set.

Anti-ageing and body composition in healthy older adults

Body-composition research in healthy older adults is frequently referenced in scientific summaries [1]. The current search did not return a 2023-2026 RCT in this population. Sample sizes, dosing regimens, and safety profiles in older non-HIV cohorts are therefore not established.

For mechanism-adjacent comparisons, the CJC-1295 profile covers a longer-acting GHRH analogue. The semaglutide entry contrasts a GLP-1 receptor agonist pathway for readers scoping non-GHRH metabolic comparators.

Tesamorelin Dosage: Clinical Trial Protocols

The clinical trial dosage for tesamorelin in HIV-associated lipodystrophy is 2 mg subcutaneously once daily, administered to the abdomen with site rotation, as reflected in the meta-analysis of randomised controlled trials underpinning the FDA-approved indication [1]. This is the only dose with a controlled-trial evidence base in the sources reviewed here.

Disclaimer: Dosage data below is drawn from HIV-population clinical trials. It does not constitute guidance for use in any other context.

The 2 mg daily protocol

The trials pooled in the 2026 meta-analysis used 2 mg/day subcutaneous tesamorelin against placebo over treatment periods extending to 52 weeks, with body composition, hepatic fat, and metabolic parameters as endpoints [1]. Injection sites are rotated across the abdomen to reduce local reactions, per the labelling underlying those trials [1].

JCSG.org supplies tesamorelin in research-grade lyophilised vial formats. Check current vial sizes and pricing on the JCSG.org product page. It is reconstituted with bacteriostatic or sterile water before use in a laboratory setting.

Population caveat

The 2 mg daily figure was validated in adults with HIV-associated lipodystrophy and excess abdominal fat. It has not been validated in healthy adults, non-HIV metabolic syndrome cohorts, older adults outside HIV populations, or any cosmetic body-composition context. No 2023-2026 RCT in those groups was identified in this evidence set.

Reconstitution and format

Tesamorelin is supplied as a lyophilised powder requiring reconstitution prior to subcutaneous administration in the trial protocols [1][4]. Specific reconstitution volumes and stability data should be drawn directly from a primary clinical pharmacology source or the manufacturer monograph rather than vendor pages.

Readers comparing GHRH-axis dosing across analogues can consult the CJC-1295 profile for the longer-acting comparator. The semaglutide entry provides a GLP-1 receptor agonist contrast on metabolic endpoints.

Tesamorelin Side Effects: Trial Evidence

The adverse-event profile documented in the published HIV-associated lipodystrophy RCT pool centres on injection-site reactions, fluid retention, joint and muscle symptoms, and shifts in glucose handling. No serious side effects were reported in the 2026 meta-analysis of randomised trials [1], which aggregated body composition, hepatic fat, metabolic, and safety endpoints across the controlled literature in HIV-positive adults on antiretroviral therapy [1].

The categories below summarise what the RCT evidence base in HIV-lipodystrophy populations has reported [1]:

• Injection-site reactions: erythema, pruritus, and pain at the subcutaneous abdominal injection site. Site rotation in trial protocols mitigated these, since repeated injections at the same location trigger local inflammatory responses.
• Fluid retention and oedema: peripheral oedema consistent with the known effect of GH-axis stimulation on sodium and water balance. GH increases renal sodium reabsorption and aquaporin-2 expression.
• Arthralgia and myalgia: joint and muscle pain consistent with downstream GH/IGF-1 effects observed across GHRH analogues. IGF-1 stimulates collagen synthesis and can trigger inflammatory responses in connective tissue.
• Glucose metabolism: elevations in fasting glucose and potential worsening of insulin sensitivity. This signal is particularly relevant given the baseline metabolic burden of the HIV-lipodystrophy cohort, since GH is a counter-regulatory hormone that antagonises insulin action.
• IGF-1 elevation: GH stimulation raises circulating IGF-1. Trial protocols incorporated IGF-1 monitoring as a routine pharmacodynamic and safety measure, because excessive IGF-1 elevation carries theoretical risks of acromegaly-like effects and malignancy.
• Hypersensitivity reactions: rare but documented in the labelling underlying the trial programme. They were not characterised quantitatively in the 2026 meta-analysis due to low frequency.

Population applicability and durability of the signal

This profile is derived from HIV-positive adults receiving antiretroviral therapy with excess abdominal fat. Whether the same frequencies, severity, or balance of injection-site versus metabolic events apply to non-HIV cohorts, healthy adults, or older adults outside HIV populations is not established by the controlled literature reviewed in the 2026 meta-analysis [1].

Long-term safety beyond the 26- to 52-week trial windows reported in that pool is similarly not characterised in the available evidence set [1].

Readers cross-referencing GH-axis safety should consult the CJC-1295 profile for a longer-acting GHRH analogue comparison. The semaglutide entry provides a GLP-1 receptor agonist with a substantively different adverse-event pattern on metabolic endpoints.

UK Regulatory Status of Tesamorelin in 2026

Tesamorelin holds no MHRA marketing authorisation in the United Kingdom as of 2026 and is not a licensed medicine in Great Britain or Northern Ireland [unverified against the MHRA public register at time of writing]. This contrasts with the United States, where the compound is approved by the FDA as Egrifta SV for the reduction of excess abdominal fat in HIV-associated lipodystrophy [4]. No equivalent UK licence, special, or named-patient route is evidenced in the sources reviewed for this guide [1].

UK research-peptide suppliers typically supply tesamorelin under "research use only" disclaimers. The Human Medicines Regulations 2012 govern the manufacture, supply, and advertising of medicinal products in the UK based on function and presentation rather than vendor disclaimers. Whether a "research use only" disclaimer insulates a supplier from the definition of a medicinal product by function or presentation has not been definitively resolved by any MHRA enforcement notice surfaced in the public domain within the sources consulted here [unverified].

Possession for personal use is a separate legal question from supply. The two should not be conflated when reading vendor pages or forum commentary. Researchers acquiring tesamorelin for in vitro or non-human work should verify the current MHRA register entry, the Home Office controlled-drug schedules (tesamorelin is not a controlled drug, but verification is prudent), and any institutional ethics requirements before procurement. Independent legal advice is warranted before any activity that could fall within the supply, importation, or advertising provisions of the 2012 Regulations.

Regulatory disclaimer

This article is a research reference, not legal, medical, or regulatory advice. Statements on UK status reflect the sources cited and the MHRA public-register position at the time of writing. Readers should reverify directly with the MHRA before relying on any claim here for procurement, institutional, or publication purposes.

Readers comparing regulatory framing across the GHRH cluster may find the CJC-1295 entry useful. Those weighing licensed metabolic alternatives should consult the semaglutide profile, where UK marketing authorisation does exist.

Tesamorelin vs Related GHRH Peptides

Tesamorelin has the strongest clinical evidence base of the GHRH analogue cluster. It is the only member with FDA approval and a 2026 meta-analysis of randomised controlled trials supporting efficacy and safety in HIV-associated lipodystrophy [1]. CJC-1295 and sermorelin appear in UK educational material as research peptides without an equivalent regulatory dossier.

Structurally, the three sit at different points on the GHRH scaffold. Sermorelin is a 29-amino-acid fragment corresponding to the biologically active N-terminus of endogenous GHRH(1-44), the region containing the receptor-binding domain [1]. Tesamorelin is the full 44-amino-acid GHRH(1-44) sequence with a trans-3-hexenoic acid group at the N-terminus, conferring resistance to DPP-4 cleavage [1].

CJC-1295 is a 30-amino-acid GHRH(1-29) analogue with four amino-acid substitutions. The "with DAC" variant adds a drug affinity complex that binds serum albumin to extend circulating half-life, protecting the peptide from proteolytic degradation. Precise half-life figures for each compound should be drawn from primary pharmacokinetic literature rather than vendor pages; the sources surfaced here do not provide such figures in citable numeric form [unverified].

Mechanism boundary: GHRH analogues vs GHRPs

Tesamorelin, CJC-1295, and sermorelin all act at the pituitary GHRH receptor and preserve pulsatile GH secretion through the same G-protein-coupled receptor pathway [1]. Ipamorelin and related growth hormone-releasing peptides act instead at the ghrelin (GHS-R1a) receptor — a mechanistically distinct pathway that is often discussed alongside GHRH analogues but is not interchangeable with them.

Stacking claims in vendor copy should be read with that pharmacological boundary in mind.

For a direct mechanistic comparison within the GHRH cluster, see the CJC-1295 entry. Readers evaluating an MHRA-licensed metabolic alternative with a different mechanism should consult the semaglutide profile.

Sourcing and Documentation

JCSG.org sources Body Pharm tesamorelin as research-grade, lyophilised stock dispatched to UK addresses. Every batch ships with a certificate of analysis covering identity (mass spectrometry), purity (HPLC ≥98%), and endotoxin testing, giving traceability from order to laboratory.

• UK dispatch to Great Britain addresses
• CoA included — identity, purity, and endotoxin data on every batch
• Current pricing shown in the buy box above

Body Pharm tesamorelin is also listed as a reference product at bodypharm.co.uk for researchers who wish to compare product specifications.

Supplied for research use only. Not for human consumption.

Tesamorelin UK Research Peptide: Quality and Sourcing

JCSG.org supplies tesamorelin in research-grade lyophilised vial formats. Quality control standards matter: always request a current certificate of analysis covering identity (mass spectrometry), purity (HPLC, typically ≥98%), and endotoxin testing. Retain batch numbers for traceability.

Browse the full Body Pharm peptide range, or check availability and current pricing in the buy box above.

This section documents market availability for research procurement context only and is not a recommendation to purchase tesamorelin for human use.

Frequently Asked Questions